LEXXW - Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy
(TheNewswire)
Kelowna, British Columbia – TheNewswire - May 21, 2024 – Lexaria Bioscience Corp. (Nasdaq: LEXX &LEXXW) (the “Company” or “Lexaria”), a global innovator indrug delivery platforms announces two important new patentawards.
The Company has received a new granted patent inLexaria’s patent family #21: Compositions and Methods for Treating Hypertension. This is the Company’s third granted US patent in thispatent family. As Lexaria has repeatedly demonstrated,DehydraTECH-processed cannabidiol (“CBD”) has evidenced an abilityto lower blood pressure in both acute dosing in hypertension as wellas over a 5-week studyduration . This patent will expire in 2042 ifnot extended.
The Company has also received a new granted patent inLexaria’s patent family #24: Compositions and Methods for Treating Epilepsy . This is the Company’s third granted US patent in thispatent family. This patent complements earlierresearch that discovered DehydraTECH-CBD wascapable of mitigating epileptic seizures in rodents, and was alsoabsorbed into the bloodstream more effectively than the commerciallyavailable cannabinoid-based anti-seizure medication, Epidiolex®. Thispatent will expire in 2042 if not extended.
With the issuance of these two new patents, Lexaria’spatent portfolio has now grown to 43 granted patents worldwide.Lexaria’s intellectual property remains a significant component insupporting future business objectives.
About Lexaria Bioscience Corp. &DehydraTECH
DehydraTECH™ is Lexaria’s patented drug deliveryformulation and processing platform technology which improves the wayactive pharmaceutical ingredients (APIs) enter the bloodstream throughoral delivery. Since 2016, Lexaria has developed and investigatedDehydraTECH with a variety of beneficial molecules in oral and topicalformats. DehydraTECH has repeatedly demonstrated the ability toincrease bio-absorption and has also evidenced an ability to deliversome drugs more effectively across the blood brain barrier, whichLexaria believes to be of particular importance for centrally activecompounds. Lexaria operates a licensed in-house research laboratoryand holds a robust intellectual property portfolio with 43 patentsgranted and many patents pending worldwide. For more information,please visit www.lexariabioscience.com .
CAUTION REGARDING FORWARD-LOOKINGSTATEMENTS
This press release includes forward-looking statements.Statements as such term is defined under applicable securities laws.These statements may be identified by words such as"anticipate," "if," "believe,""plan," "estimate," "expect,""intend," "may," "could,""should," "will," and other similar expressions.Such forward-looking statements in this press release include, but arenot limited to, statements by the company relating the Company’sability to carry out research initiatives, receive regulatoryapprovals or grants or experience positive effects or results from anyresearch or study. Such forward-looking statements are estimatesreflecting the Company's best judgment based upon current informationand involve a number of risks and uncertainties, and there can be noassurance that the Company will actually achieve the plans,intentions, or expectations disclosed in these forward-lookingstatements. As such, you should not place undue reliance on theseforward-looking statements. Factors which could cause actual resultsto differ materially from those estimated by the Company include, butare not limited to, government regulation and regulatory approvals,managing and maintaining growth, the effect of adverse publicity,litigation, competition, scientific discovery, the patent applicationand approval process, potential adverse effects arising from thetesting or use of products utilizing the DehydraTECH technology, theCompany’s ability to maintain existing collaborations and realizethe benefits thereof, delays or cancellations of planned R&D thatcould occur related to pandemics or for other reasons, and otherfactors which may be identified from time to time in the Company'spublic announcements and periodic filings withthe US Securities and Exchange Commission on EDGAR. The Companyprovides links to third-party websites only as a courtesy to readersand disclaims any responsibility for the thoroughness, accuracy ortimeliness of information at third-party websites. There is noassurance that any of Lexaria’s postulated uses, benefits, oradvantages for the patented and patent-pending technology will in factbe realized in any manner or in any part. No statement herein has beenevaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat,cure or prevent any disease. Any forward-looking statements containedin this release speak only as of the date hereof, and the Companyexpressly disclaims any obligation to update any forward-lookingstatements or links to third-party websites contained herein, whetheras a result of any new information, future events, changedcircumstances or otherwise, except as otherwise required bylaw.
INVESTOR CONTACT:
George Jurcic - Head of InvestorRelations
Copyright (c) 2024 TheNewswire - All rights reserved.